ArticleScientific reports2025
Revealing the role of U2AF1 in splicing regulation and chimeric RNA dynamics.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Goldilocks state of transcriptional readthrough for chimeric splicing.Transcription · 2026Review
- Mutational Spectrum and Clinical Outcomes of Myelodysplastic/Myeloproliferative Neoplasms: A Single-Institution Study in Korea with Emphasis onJournal of clinical medicine · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
U2 small nuclear ribonucleoprotein auxiliary factor 1 (U2AF1) gene is a pivotal splicing factor frequently mutated in various malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). U2AF1 plays a critical role in the recognition and processing of 3' splice sites during pre-mRNA splicing, thereby contributing to the regulation of gene expression and the generation of protein diversity. However, how U2AF1 contributes to the formation and regulation of different categories of chimeric RNAs remains elusive. In this study, we aimed to elucidate the involvement of U2AF1 in chimeric RNA formation and its regulatory impact on different categories of chimeric RNA. Employing knockdown and overexpression strategies in leukemia and esophageal cancer cell lines, we conducted paired-end RNA sequencing following U2AF1 knockdown to assess transcriptomic alterations and their influence on alternative splicing patterns. Subsequently, we utilized the SOAPfuse algorithm to detect and characterize chimeric RNAs from the paired-end RNA sequencing data. Our findings unveiled significant changes in the landscape of chimeric RNA upon U2AF1 knockdown, highlighting its critical role in chimeric RNA formation. This study provides novel insights into how U2AF1 mediates chimeric RNA formation and regulates distinct categories of chimeric RNA within leukemia cell lines. Thereby highlighting its potential as a biomarker for leukemia and other malignancies, promising avenues for future diagnostic and therapeutic developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.